Research graph
References from Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study. Local targets link to admitted publications; unresolved targets remain external evidence.
Recurrence and progression of disease in Non–muscle-invasive bladder cancer: from epidemiology to treatment strategy
10.1016/j.eururo.2009.06.028 · 2009 · External reference
Adherence to surveillance among patients with superficial bladder cancer
10.1093/jnci/95.8.588 · 2003 · External reference
Evaluation of the relationship between compliance with the follow-up and treatment protocol and health literacy in bladder tumor patients
10.1080/13685538.2018.1447558 · 2019 · External reference
Compliance with guidelines for patients with bladder cancer: variation in the delivery of care
10.1002/cncr.26198 · 2011 · External reference
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer
10.1016/j.urolonc.2014.06.008 · 2015 · External reference
Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer
10.1016/j.urolonc.2012.09.011 · 2014 · External reference
Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution
10.1002/cncy.21477 · 2015 · External reference
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment
10.1097/ju.0000000000003846 · 2024 · External reference
Diagnostic value of urine cytology in bladder cancer. A meta-analysis
2016 · External reference
Urinary markers for bladder cancer diagnosis: a review of current status and future challenges
10.1111/iju.15338 · 2024 · External reference
Bladder cancer biomarkers: current approaches and future directions
10.3389/fonc.2024.1453278 · 2024 · External reference
Cell-free DNA fragmentomics: the novel promising biomarker
10.3390/ijms24021503 · 2023 · External reference
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
10.1038/s41591-019-0652-7 · 2019 · External reference
Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation
10.1186/1471-2164-16-s13-s1 · 2015 · External reference
Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin
10.1016/j.cell.2015.11.050 · 2016 · External reference
Development and validation of a cell-free DNA fragmentomics–based model for early detection of pancreatic cancer
2025 · External reference
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer
10.1038/s41467-025-61890-z · 2025 · External reference
10.1164/rccm.202109-2019oc
10.1164/rccm.202109-2019oc · External reference
Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma
2024 · External reference
Multidimensional fragmentomics enables early and accurate detection of colorectal cancer
10.1158/0008-5472.can-23-3486 · 2024 · External reference
Cell-free DNA fragmentomics: a promising biomarker for diagnosis, prognosis and prediction of response in breast cancer
10.3390/ijms232214197 · 2022 · External reference
Detection and characterization of lung cancer using cell-free DNA fragmentomes
10.1038/s41467-021-24994-w · 2021 · External reference
Bladder cancer
10.1016/s0140-6736(16)30512-8 · 2016 · External reference
Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk?
10.1186/s12894-023-01278-7 · 2023 · External reference
European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update
10.1016/j.eururo.2024.07.027 · 2024 · External reference
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease
10.1038/s41467-018-07466-6 · 2018 · External reference
Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology
10.1038/s41467-024-46435-0 · 2024 · External reference
Cell-free DNA–derived immune cell ratios uncover cancer-associated systemic changes
10.1158/2767-9764.crc-25-0747 · 2026 · External reference
Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammation
10.1111/cas.14679 · 2021 · External reference
Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA
10.1186/s13073-022-01125-8 · 2022 · External reference
Detection of bladder cancer using a point-of-care proteomic assay
10.1001/jama.293.7.810 · 2005 · External reference
Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: a pilot study
10.3892/mco.2021.2415 · 2021 · External reference
A urine-based liquid biopsy method for detection of upper tract urinary carcinoma
10.3389/fonc.2020.597486 · 2021 · External reference
Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis
10.1016/j.euo.2020.02.007 · 2020 · External reference
Detection of bladder cancer using a point-of-care proteomic assay
10.1001/jama.293.7.810 · ExternalCitation · doi-reference
Compliance with guidelines for patients with bladder cancer: variation in the delivery of care
10.1002/cncr.26198 · ExternalCitation · doi-reference
Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution
10.1002/cncy.21477 · ExternalCitation · doi-reference
Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin
10.1016/j.cell.2015.11.050 · ExternalCitation · doi-reference
Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis
10.1016/j.euo.2020.02.007 · ExternalCitation · doi-reference
Recurrence and progression of disease in Non–muscle-invasive bladder cancer: from epidemiology to treatment strategy
10.1016/j.eururo.2009.06.028 · ExternalCitation · doi-reference
European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update
10.1016/j.eururo.2024.07.027 · ExternalCitation · doi-reference
Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer
10.1016/j.urolonc.2012.09.011 · ExternalCitation · doi-reference
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer
10.1016/j.urolonc.2014.06.008 · ExternalCitation · doi-reference
Bladder cancer
10.1016/s0140-6736(16)30512-8 · ExternalCitation · doi-reference
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease
10.1038/s41467-018-07466-6 · ExternalCitation · doi-reference
Detection and characterization of lung cancer using cell-free DNA fragmentomes
10.1038/s41467-021-24994-w · ExternalCitation · doi-reference
Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology
10.1038/s41467-024-46435-0 · ExternalCitation · doi-reference
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer
10.1038/s41467-025-61890-z · ExternalCitation · doi-reference
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
10.1038/s41591-019-0652-7 · ExternalCitation · doi-reference
Evaluation of the relationship between compliance with the follow-up and treatment protocol and health literacy in bladder tumor patients
10.1080/13685538.2018.1447558 · ExternalCitation · doi-reference
Adherence to surveillance among patients with superficial bladder cancer
10.1093/jnci/95.8.588 · ExternalCitation · doi-reference
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment
10.1097/ju.0000000000003846 · ExternalCitation · doi-reference
Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammation
10.1111/cas.14679 · ExternalCitation · doi-reference
Urinary markers for bladder cancer diagnosis: a review of current status and future challenges
10.1111/iju.15338 · ExternalCitation · doi-reference
Multidimensional fragmentomics enables early and accurate detection of colorectal cancer
10.1158/0008-5472.can-23-3486 · ExternalCitation · doi-reference
Cell-free DNA–derived immune cell ratios uncover cancer-associated systemic changes
10.1158/2767-9764.crc-25-0747 · ExternalCitation · doi-reference
10.1164/rccm.202109-2019oc
10.1164/rccm.202109-2019oc · ExternalCitation · doi-reference
Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation
10.1186/1471-2164-16-s13-s1 · ExternalCitation · doi-reference
Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk?
10.1186/s12894-023-01278-7 · ExternalCitation · doi-reference
Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA
10.1186/s13073-022-01125-8 · ExternalCitation · doi-reference
A urine-based liquid biopsy method for detection of upper tract urinary carcinoma
10.3389/fonc.2020.597486 · ExternalCitation · doi-reference
Bladder cancer biomarkers: current approaches and future directions
10.3389/fonc.2024.1453278 · ExternalCitation · doi-reference
Cell-free DNA fragmentomics: a promising biomarker for diagnosis, prognosis and prediction of response in breast cancer
10.3390/ijms232214197 · ExternalCitation · doi-reference
Cell-free DNA fragmentomics: the novel promising biomarker
10.3390/ijms24021503 · ExternalCitation · doi-reference
Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: a pilot study
10.3892/mco.2021.2415 · ExternalCitation · doi-reference
